albuterol has been researched along with Infant, Premature, Diseases in 14 studies
Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.
albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
Infant, Premature, Diseases: Diseases that occur in PREMATURE INFANTS.
Excerpt | Relevance | Reference |
---|---|---|
"Seven infants had acute renal failure, two had persistent metabolic acidosis without renal failure and the remaining infant had a combination of acute renal failure and persistent metabolic acidosis." | 1.28 | Salbutamol infusion to treat neonatal hyperkalaemia. ( Brooker, R; Emery, EF; Gamsu, HR; Greenough, A, 1992) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 5 (35.71) | 18.2507 |
2000's | 6 (42.86) | 29.6817 |
2010's | 3 (21.43) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ng, G | 2 |
da Silva, O | 2 |
Ohlsson, A | 4 |
Vemgal, P | 2 |
Mildenberger, E | 1 |
Versmold, HT | 1 |
Thomas, MR | 1 |
Rafferty, GF | 1 |
Blowes, R | 1 |
Peacock, JL | 1 |
Marlow, N | 1 |
Calvert, S | 1 |
Milner, A | 1 |
Greenough, A | 3 |
O'Hare, FM | 1 |
Molloy, EJ | 1 |
Yaseen, H | 1 |
Khalaf, M | 1 |
Dana, A | 1 |
Yaseen, N | 1 |
Darwich, M | 1 |
Derish, M | 1 |
Hodge, G | 1 |
Dunn, C | 1 |
Ariagno, R | 1 |
Denjean, A | 1 |
Paris-Llado, J | 1 |
Zupan, V | 1 |
Debillon, T | 1 |
Kieffer, F | 1 |
Magny, JF | 1 |
Desfrères, L | 1 |
Llanas, B | 1 |
Guimaraes, H | 1 |
Moriette, G | 1 |
Voyer, M | 1 |
Dehan, M | 1 |
Breart, G | 1 |
Sivakumar, D | 1 |
Bosque, E | 1 |
Goldman, SL | 1 |
Khalaf, MN | 1 |
Hurley, JF | 1 |
Bhandari, V | 1 |
Emery, EF | 1 |
Brooker, R | 1 |
Gamsu, HR | 1 |
Yuksel, B | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Albuterol Dose-Response on Pulmonary Function Testing in Preterm Infants at Risk of Bronchopulmonary Dysplasia[NCT02447250] | Phase 4 | 14 participants (Actual) | Interventional | 2013-10-24 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Mothers who smoked cigarettes during pregnancy and the rate of albuterol response of their infants (NCT02447250)
Timeframe: Smoking and second hand smoke exposure history will be obtained at enrollment. Albuterol response will be obtained within one week.
Intervention | participants (Number) | |
---|---|---|
albuterol responders of mothers who smoked | albuterol responders of non-smoker mothers % | |
Single Arm: Varied Albuterol Dose Response | 4 | 6 |
birth weight in grams of each subject was recorded at time of enrollment (NCT02447250)
Timeframe: within one week of entering study
Intervention | grams (Mean) | |
---|---|---|
albuterol responders | albuterol non responders | |
Single Arm: Varied Albuterol Dose Response | 847.2 | 1147.7 |
The primary outcome is the percentage of subjects who show a positive response to each dose of albuterol. A positive response is defined as a greater than or equal to 10% decrease in respiratory resistance (Rrs). The change in RRs was measured at baseline and again after each dose of albuterol. All measurements were taken within a 7 day time frame for each subject such that each subject would have up to 3 results measured during a 7 day period, if he/she were able to complete three sets of PFTs according to study protocol. The change in Rrs was calculated by subtracting the baseline Rrs from the post-albuterol Rrs. (NCT02447250)
Timeframe: Within one week of performing pulmonary function tests
Intervention | cm h2o/mL/sec (Mean) | ||
---|---|---|---|
dose 1 | dose 2 | dose 3 | |
Single Arm: Varied Albuterol Dose Response | 0.011 | 0.006 | 0.014 |
Reason for each subject's preterm delivery was classified as either preterm labor or delivery for maternal indications (eg pre-eclampsia). (NCT02447250)
Timeframe: within one week of entering study
Intervention | Participants (Count of Participants) | |
---|---|---|
preterm labor, responsive to albuterol | maternal indicated delivery, responsive to albuter | |
Single Arm: Varied Albuterol Dose Response | 4 | 6 |
Family history was obtained from verbal history by subject's mother at time of enrollment in study. A positive family history was noted if a first degree relative of the subject (infant) had a diagnosis of asthma. (NCT02447250)
Timeframe: History collected at enrollment, albuterol response assessed within one week
Intervention | participants (Number) | |
---|---|---|
family hx of asthma, respond to albuterol | no fam hx asthma, respond to albuterol | |
Single Arm: Varied Albuterol Dose Response | 1 | 9 |
Average gestational age (GA) in weeks at birth for subjects who responded to albuterol versus subjects without a positive response (NCT02447250)
Timeframe: within one week of entering study
Intervention | weeks (Mean) | |
---|---|---|
birth GA albuterol responders, weeks | birth GA albuterol non responders | |
Single Arm: Varied Albuterol Dose Response | 26.7 | 28.5 |
Maternal BMI will be obtained from her medial record, and she will be asked about weight gain during pregnancy at time of enrollment. Results will be compared for infants born to women with a normal BMI vs. those with obese BMI (>30). (NCT02447250)
Timeframe: Maternal information collected at enrollment; albuterol response assessed within one week
Intervention | kg/m^2 (Mean) | |
---|---|---|
mean BMI mothers of albuterol-responders , any dos | mean BMI mothers of albuterol non-responders | |
Single Arm: Varied Albuterol Dose Response | 27.4 | 27.3 |
Compare number of subjects who have a positive response (greater than or equal to 10% decrease in respiratory resistance) to each dose of albuterol (NCT02447250)
Timeframe: Data collected 15 minutes after dose in each session. Study includes 3 sessions within a 7 day period.
Intervention | participants (Number) | ||
---|---|---|---|
positive Rrs response at 180 mcg albuterol | positive Rrs response at 270 mcg albuterol | positive Rrs response at 360 mcg albuterol | |
Single Arm: Varied Albuterol Dose Response | 6 | 4 | 4 |
6 reviews available for albuterol and Infant, Premature, Diseases
Article | Year |
---|---|
Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants.
Topics: Albuterol; Aminophylline; Beclomethasone; Bronchodilator Agents; Chronic Disease; Drug Therapy, Comb | 2016 |
Interventions for non-oliguric hyperkalaemia in preterm neonates.
Topics: Albuterol; Glucose; Humans; Hyperkalemia; Infant, Newborn; Infant, Premature; Infant, Premature, Dis | 2012 |
Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants.
Topics: Albuterol; Beclomethasone; Bronchodilator Agents; Chronic Disease; Humans; Infant, Newborn; Infant, | 2012 |
Pathogenesis and therapy of non-oliguric hyperkalaemia of the premature infant.
Topics: Adrenergic beta-Agonists; Albuterol; Calcium; Diuretics; Evidence-Based Medicine; Exchange Transfusi | 2002 |
Interventions for non-oliguric hyperkalaemia in preterm neonates.
Topics: Albuterol; Glucose; Humans; Hyperkalemia; Infant, Newborn; Infant, Premature; Infant, Premature, Dis | 2007 |
What is the best treatment for hyperkalaemia in a preterm infant?
Topics: Albuterol; Calcium Gluconate; Evidence-Based Medicine; Exchange Transfusion, Whole Blood; Humans; Hy | 2008 |
4 trials available for albuterol and Infant, Premature, Diseases
Article | Year |
---|---|
Inhaled salbutamol and beclomethasone for preventing broncho-pulmonary dysplasia: a randomised double-blind study.
Topics: Administration, Inhalation; Albuterol; Beclomethasone; Bronchodilator Agents; Bronchopulmonary Dyspl | 1998 |
Bronchodilator delivered by metered dose inhaler and spacer improves respiratory system compliance more than nebulizer-delivered bronchodilator in ventilated premature infants.
Topics: Administration, Inhalation; Albuterol; Analysis of Variance; Bronchodilator Agents; Cross-Over Studi | 1999 |
A prospective controlled trial of albuterol aerosol delivered via metered dose inhaler-spacer device (MDI) versus jet nebulizer in ventilated preterm neonates.
Topics: Administration, Inhalation; Albuterol; Bronchodilator Agents; Humans; Infant, Newborn; Infant, Prema | 2001 |
Effect of nebulized salbutamol in preterm infants during the first year of life.
Topics: Aerosols; Albuterol; Cough; Female; Humans; Infant; Infant, Newborn; Infant, Premature, Diseases; Lu | 1991 |
4 other studies available for albuterol and Infant, Premature, Diseases
Article | Year |
---|---|
Plethysmograph and interrupter resistance measurements in prematurely born young children.
Topics: Airway Obstruction; Airway Resistance; Albuterol; Bronchodilator Agents; Functional Residual Capacit | 2006 |
Salbutamol versus cation-exchange resin (kayexalate) for the treatment of nonoliguric hyperkalemia in preterm infants.
Topics: Adrenergic beta-Agonists; Albuterol; Cation Exchange Resins; Female; Humans; Hyperkalemia; Infant, N | 2008 |
Aerosolized albuterol improves airway reactivity in infants with acute respiratory failure from respiratory syncytial virus.
Topics: Acute Disease; Adrenergic beta-Agonists; Aerosols; Albuterol; Functional Residual Capacity; Humans; | 1998 |
Salbutamol infusion to treat neonatal hyperkalaemia.
Topics: Acidosis; Acute Kidney Injury; Albuterol; Female; Humans; Hyperkalemia; Infant, Low Birth Weight; In | 1992 |